Where to Buy Retatrutide in 2026: Vendors With Published Lab Results

Retatrutide is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors. It is not an approved medicine anywhere, no pharmacy legally sells it, and the FDA has issued warning letters to companies selling compounded versions — six companies (five in the US, one in Germany) in the initial round, with further letters following into 2026. What exists instead is a gray market of research-chemical vendors, and their quality varies enormously. In 2024, roughly 43% of research peptides submitted to Janoshik Analytical, the industry’s busiest independent lab, failed to meet their label purity claims. (Treat that number as an order-of-magnitude warning rather than a precise statistic — it includes private and withdrawn submissions.)

That gap between label and vial is the entire problem this guide solves. The short version: never judge a retatrutide vendor by their website. Judge them by their published, third-party, batch-specific lab results.

Why demand exploded

Retatrutide’s phase 2 trial reported a mean 24.2% weight reduction at 48 weeks on the highest dose, and the first phase 3 results (TRIUMPH-1, May 2026) went further: −25.0% at 80 weeks on 12 mg, reaching −30.3% in the 104-week extension . Those are numbers historically associated with bariatric surgery (Lilly). Results like that, years ahead of any possible approval, are why the gray market exists. Full trial data lives in our retatrutide dosage guide.

The legal reality first

Retatrutide is sold “for research purposes only.” It is not FDA-approved, and there is no legal route to buy it as a medicine: because retatrutide has no USP monograph, is not a component of any approved drug, and appears on neither the 503A nor 503B bulks lists, even licensed compounding pharmacies cannot legally make it. That is exactly what the FDA’s warning letters say. Mainstream coverage (Forbes Health, a CBS News investigation into online sellers) has documented both the safety concerns and the reality that it is widely available anyway. Nothing in this article is medical advice; it documents what the published testing record says about the vendors selling this compound.

How to evaluate a retatrutide vendor in five checks

1. Batch-specific COAs, publicly posted. A certificate for your batch number, not a generic “99% purity” badge. No published COA, no order.
2. Third-party lab, verifiable report. The COA should come from an independent analytical lab, ideally one with a public verification tool, so you can confirm the report is real rather than a graphic a designer made. See our data sources for the labs that dominate this industry.
3. Tested quantity, not just purity. A vial can be 99% pure retatrutide and still contain 6mg against a 10mg label. Quantity testing is where vendors quietly fail.
4. Recent results. A great COA from a year ago says nothing about this month’s batch. Check the test date.
5. Realistic pricing. Track the market price per milligram; a price dramatically below market is its own data point.

Vendors ranked by published lab results

We do not hand-pick recommendations. Vendor rankings on PeptideCensus are generated from publicly published, batch-specific third-party lab results, refreshed daily, and free to view. Start with the live vendor rankings and open any profile to see the published record behind its score. Per-peptide leaderboards, including retatrutide-specific batch tables, roll out as the index grows.

What retatrutide actually costs

The right unit of comparison is price per milligram: vial price ÷ labeled milligrams, then adjusted by what the batch actually tested at, because an underdosed vial silently raises the real price. Listed vial prices vary several-fold between vendors for the same claimed contents, which is exactly why the comparison has to be done per-mg and per-tested-mg rather than per-vial.

Current per-vendor pricing sits alongside each score on the vendor rankings. Compare the price-per-mg column there instead of any single vendor’s marketing page.

Red flags that end the conversation

• “Lab tested” claims with no viewable report
• COAs with no batch number, no lab name, or no verification path
• Compounded or “pharma grade” retatrutide claims: the FDA’s letters make clear no compounded version is legal, and several warned vendors sold it under coded names
• Sites selling the same vial sizes at wildly fluctuating prices week to week
• Vendors that have appeared on failed-batch lists and never addressed it

Buying from Canada?

Different customs rules, different vendor pool, same testing logic. All covered separately in our Canada buying guide.

Common questions

Is it legal to buy retatrutide? There is no legal route to buy it as a medicine. Research-chemical sales occupy a gray zone: sold for laboratory use only, with the FDA actively sending warning letters to sellers marketing it for human use.

Can I get compounded retatrutide from a pharmacy or med spa? No — legally, nobody can compound it. Any “compounded retatrutide” offer is operating outside the rules the FDA’s warning letters spell out.

When will retatrutide be approved? Phase 3 trials (the TRIUMPH program) reported first results in May 2026; approval timing is Lilly’s and regulators’ call, and any specific date you read is speculation.

How do I verify a vendor’s COA is real? Match the batch number on the certificate to your vial, and use the issuing lab’s public verification tool where one exists; our sources page lists them.

What does a fair price look like? Compute price per milligram and compare it against the market median on our tracker. A price far below market is a warning, not a deal.

Before you order: check the batch

Whatever vendor you choose, look up their latest published batch on their PeptideCensus profile first, and run your numbers through the peptide calculator only after confirming the vial’s tested contents. The math is only as good as the vial.